Fibromyalgia - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 80
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FAEBA0B04C6EN
Leaflet:

Download PDF Leaflet

Fibromyalgia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Fibromyalgia - Pipeline Review, H2 2016’, provides an overview of the Fibromyalgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibromyalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Fibromyalgia
  • The report reviews pipeline therapeutics for Fibromyalgia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fibromyalgia therapeutics and enlists all their major and minor projects
  • The report assesses Fibromyalgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fibromyalgia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fibromyalgia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Fibromyalgia Overview
Therapeutics Development
Pipeline Products for Fibromyalgia - Overview
Pipeline Products for Fibromyalgia - Comparative Analysis
Fibromyalgia - Therapeutics under Development by Companies
Fibromyalgia - Therapeutics under Investigation by Universities/Institutes
Fibromyalgia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fibromyalgia - Products under Development by Companies
Fibromyalgia - Products under Investigation by Universities/Institutes
Fibromyalgia - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
SWITCH Biotech LLC
Theravance Biopharma, Inc.
Tonix Pharmaceuticals Holding Corp.
Zynerba Pharmaceuticals, Inc.
Fibromyalgia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1069562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-8062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXIBU-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirtazapine ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SWT-06101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-9855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibromyalgia - Dormant Projects
Fibromyalgia - Discontinued Products
Fibromyalgia - Product Development Milestones
Featured News & Press Releases
Jun 09, 2016: Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
May 02, 2016: Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
Nov 10, 2015: Tonix Pharmaceuticals Presents Additional Data on Tonmya Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting
Oct 01, 2015: Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting
Jun 17, 2015: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg
Jun 11, 2015: Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR
May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
May 20, 2015: Tonix Pharmaceuticals to Present Additional Data From Completed Phase 2b Study of TNX-102 SL in Fibromyalgia at EULAR
May 13, 2015: Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Fibromyalgia, H2 2016
Number of Products under Development for Fibromyalgia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Fibromyalgia - Pipeline by Astellas Pharma Inc., H2 2016
Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Fibromyalgia - Pipeline by Merck & Co., Inc., H2 2016
Fibromyalgia - Pipeline by SWITCH Biotech LLC, H2 2016
Fibromyalgia - Pipeline by Theravance Biopharma, Inc., H2 2016
Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
Fibromyalgia - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Fibromyalgia - Dormant Projects, H2 2016
Fibromyalgia - Dormant Projects (Contd..1), H2 2016
Fibromyalgia - Dormant Projects (Contd..2), H2 2016
Fibromyalgia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Fibromyalgia, H2 2016
Number of Products under Development for Fibromyalgia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Astellas Pharma Inc.
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
SWITCH Biotech LLC
Theravance Biopharma, Inc.
Tonix Pharmaceuticals Holding Corp.
Zynerba Pharmaceuticals, Inc.
Skip to top


Nordic Bioscience A/S - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 27 pages
Keratitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 83 pages
Acinetobacter Infections - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 118 pages

Ask Your Question

Fibromyalgia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: